Miranda Jayne Toledano - Jul 16, 2025 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Role: Chief Executive Officer, Director
Signature: /s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Stock symbol: ENTX
Transactions as of: Jul 16, 2025
Transactions value $: $0
Form type: 4
Date filed: 7/18/2025, 04:37 PM
Previous filing: Jul 7, 2025
Next filing: Aug 7, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Toledano Miranda Jayne	Chief Executive Officer, Director	KIRYAT HADASSAH,, MINRAV BUILDING, 5TH FLOOR, JERUSALEM, ISRAEL	/s/ Dana Yaacov-Garbeli, Attorney-in-Fact	2025-07-18	0001686530

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Award	$0	+137K	+58.26%	$0.00	372K	Jul 16, 2025	Direct	F1
transaction	ENTX	Ordinary Shares, par value NIS 0.0000769 per share	Award	$0	+43.9K	+11.8%	$0.00	416K	Jul 16, 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ENTX	Stock Option (Right to Buy)	Award	$0	+500K		$0.00	500K	Jul 16, 2025	Ordinary Shares, par value NIS 0.0000769 per share	500K	$2.28	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. This grant was awarded to the Reporting Person in lieu of the Reporting Person's 2024 annual cash bonus. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 28, 2025.
F2	Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. This grant was awarded to the Reporting Person in lieu of $100,000 the Reporting Person is entitled to under the Reporting Person's base salary for 2025. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 1, 2025.
F3	This grant of options was approved by the Board on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. The options vest over a three-year period that commenced on April 28, 2025, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.